A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

23Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/β and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies. Patients and methods: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity. Results: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRα/β or FGF, and activity of tivozanib. Conclusion: Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS.

References Powered by Scopus

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

22776Citations
N/AReaders
Get full text

Cancer statistics, 2015

12163Citations
N/AReaders
Get full text

What is the evidence that tumors are angiogenesis dependent?

4511Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions

280Citations
N/AReaders
Get full text

First-Line Therapy for Metastatic Soft Tissue Sarcoma

79Citations
N/AReaders
Get full text

Systemic treatment in advanced soft tissue sarcoma: What is standard, what is new

65Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Agulnik, M., Costa, R. L. B., Milhem, M., Rademaker, A. W., Prunder, B. C., Daniels, D., … Van Tine, B. A. (2017). A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Annals of Oncology, 28(1), 121–127. https://doi.org/10.1093/annonc/mdw444

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

59%

Researcher 5

23%

Lecturer / Post doc 4

18%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

52%

Nursing and Health Professions 6

26%

Pharmacology, Toxicology and Pharmaceut... 3

13%

Computer Science 2

9%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free